Reflux After Sleeve Gastrectomy

Yes — conversion to gastric bypass is considered the gold standard for refractory GERD after a sleeve (Cymbal et al., Surgery for Obesity and Related Diseases, 2026). The sleeve creates a narrow, high-pressure stomach tube that commonly causes persistent or new reflux; at 8 years, conclusive GERD was found in about 95% of sleeve patients versus 25% after bypass (Navarini et al., World Journal of Surgery, 2026). Conversion relieves reflux in most patients and gets the majority off antacid medication, and the benefit occurs independent of how much additional weight is lost — patients who meet objective ACG reflux criteria benefit most (Cymbal et al., Surgery for Obesity and Related Diseases, 2026). In conversion series, GERD resolution reaches roughly four in five patients at one year and over nine in ten at two years (Cymbal et al., Surgery for Obesity and Related Diseases, 2026).

‍

A sleeve gastrectomy creates a narrow, high-pressure gastric tube that often causes or worsens acid reflux, and reflux is the single most common reason sleeves are revised (Clapp et al., SOARD, 2024). Converting to a Roux-en-Y gastric bypass creates a small, low-pressure, rapid-emptying pouch and diverts acid and bile away from the esophagus, making it the gold-standard fix for refractory GERD after a sleeve, with symptom resolution reported in 60–100% of patients (Thá Nassif et al., Obesity Surgery, 2025; Rapolti et al., J Laparoendosc Adv Surg Tech, 2024).

‍

Sometimes. Hiatal hernia repair, a ligament wrap, or a magnetic ring can help selected patients, but only if the esophagus squeezes normally and the sleeve is open with no twist or stricture. These options have weaker long-term evidence than conversion to a gastric bypass.

Conversion to Roux-en-Y gastric bypass is generally the most effective option for severe reflux after a sleeve gastrectomy. The bypass lowers pressure in the stomach and diverts acid and bile away from the esophagus, and any hiatal hernia is repaired at the same operation. Conversions such as SADI-S or duodenal switch keep the high-pressure sleeve and are generally not recommended when reflux is the main problem. Testing with endoscopy and sometimes pH monitoring confirms the diagnosis and checks for Barrett's esophagus before surgery.

Cardiopexy is the less invasive, sleeve-preserving option with lower short-term reoperation rates (about 3.4% vs. roughly 6.7%) and a 1.3–1.5 day stay, and it is ideal for patients who have already lost enough weight and simply want to come off reflux medication (Dore and Cherng, JOMI, 2024). Conversion to Roux-en-Y gastric bypass is the more definitive and most evidence-supported treatment for refractory reflux and is preferred when a patient needs more weight loss, has a retained/dilated fundus, has an abnormal sleeve, or has severe disease (Rapolti et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2024). The right choice depends on anatomy, weight-loss goals, and reflux severity.

‍

In bariatric series, results are encouraging in the short to medium term: 80–86.6% of patients report improvement or resolution of GERD symptoms, up to 81% reduce or stop acid medication by one year, and gastric migration is prevented in about 93% of patients (Dore and Cherng, JOMI, 2024; Rapolti et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2024). The honest caveat is durability: as a standalone reflux operation in non-bariatric patients, cardiopexy underperformed Nissen fundoplication at one year in the only randomized trial, and long-term post-sleeve data are still limited (Janssen et al., British Journal of Surgery, 1993; Runkel et al., Obesity Surgery, 2020).

‍

It is an antireflux operation that uses the round ligament of the liver (the ligamentum teres) as a sling around the lower esophagus to reinforce the reflux valve and anchor the stomach below the diaphragm (Runkel et al., Obesity Surgery, 2020). It matters after a sleeve because the gastric fundus — the part of the stomach used to build a traditional Nissen or Toupet fundoplication — was removed during the sleeve, so a standard wrap is not possible. The round ligament provides alternative tissue to rebuild an antireflux barrier while preserving the sleeve and avoiding conversion to gastric bypass (Dore and Cherng, JOMI, 2024).

‍

Yes, in the right patient. LINX is one of the few good surgical options for reflux after a sleeve. In carefully selected patients it can control symptoms and end daily acid-reducing medication without a larger conversion operation (Grover and Khaitan, Diseases of the Esophagus, 2023; Patel et al., Surgical Endoscopy, 2022). The key word is "selected," and the most important selection criterion is a proven, normally functioning esophagus.

Reflux is common after sleeve gastrectomy, affecting roughly 20–30% of patients over the long term (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026). A standard fundoplication such as a Nissen usually is not possible after a sleeve, because the fundus used to build the wrap was removed (Patel et al., Surgical Endoscopy, 2022). LINX avoids that problem. It is a ring of magnetic titanium beads placed laparoscopically around the lower esophageal sphincter to keep a weak valve closed while still allowing swallowing (Khaitan et al., Obesity Surgery, 2023).

Why esophageal function must be proven normal first:

• The esophagus has to open the device. A fundoplication still relaxes naturally when you swallow. The LINX magnets stay closed until food is pushed through them, so all the work falls on the contraction strength of the esophagus (Eriksson et al., Diseases of the Esophagus, 2023).
• Weak or absent peristalsis means trouble swallowing. An esophagus without enough pushing power may not be able to open the magnets, which can cause persistent difficulty swallowing. The FDA instructions for use list these as precautions:
  • Distal esophageal contractions weaker than 35 mmHg.
  • Fewer than 70% effective (propulsive) swallows.
  • Known motility disorders such as achalasia, distal esophageal spasm, nutcracker esophagus, or a hypertensive lower esophageal sphincter (Telem et al., Surgical Endoscopy, 2017).

An esophagus with no peristalsis at all (aperistalsis) rules out LINX (Bell, The Esophagus, 2021).

• Reflux can be mimicked. Achalasia can cause heartburn and regurgitation that look like GERD. Performing an antireflux procedure on a misdiagnosed patient can cause severe swallowing problems. For that reason, the American College of Gastroenterology recommends high-resolution manometry before any antireflux procedure and specifically before LINX (Katz et al., American College of Gastroenterology, 2022).
• Contractile reserve matters. In the prospective post-sleeve LINX study, patients qualified only if they had one of two findings (Novia et al., Surgical Endoscopy, 2025):
  • Normal esophageal motility.
  • Mildly ineffective motility that still showed adequate strength ("reserve") when tested with multiple rapid swallows.

Patients with achalasia, outflow obstruction at the esophagogastric junction (EGJOO), or aperistalsis were excluded.

When patients are chosen this way, results after a sleeve are encouraging:

• Systematic review: 14 studies and 109 patients. Reflux quality-of-life scores improved markedly (GERD-HRQL 38 → 10), and daily PPI use fell from 97.4% to 25.3% at a median of about 19 months (Cammarata et al., Obesity Surgery, 2024).

• Prospective trial: 30 patients, with a significant reduction in daily PPI use in about 96% at 12 months (Khaitan et al., Obesity Surgery, 2023).

• Other series: One series reported that 82% of patients stopped acid medication (Patel et al., Surgical Endoscopy, 2022). A prospective study showed objective normalization of acid exposure in about 64% (Novia et al., Surgical Endoscopy, 2025).

Other requirements for success:

• Hiatal repair: Repairing the hiatus at the same operation is considered essential (Grover and Khaitan, Diseases of the Esophagus, 2023).
• Relative contraindications: Conversion to gastric bypass is usually the better answer in patients with any of the following (Novia et al., Surgical Endoscopy, 2025):
  • BMI of 35 or higher.
  • Hiatal hernia larger than about 3 cm.
  • Severe (grade C–D) esophagitis.
  • Barrett's esophagus.
  • A twisted or narrowed sleeve.

• Side effects: Device-related side effects, mostly temporary swallowing difficulty, occur in about a third of patients. Removal for esophageal erosion is rare, at about 0.9% (Cammarata et al., Obesity Surgery, 2024).

Where LINX sits among the options: conversion to Roux-en-Y gastric bypass remains the most effective and most evidence-supported treatment for refractory reflux after a sleeve. It resolves symptoms in 60–100% of patients and is preferred when BMI is above 35, the sleeve anatomy is abnormal, or esophageal function is impaired (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026). LINX is best reserved for patients who meet all of these criteria:

• A normal sleeve.

• A BMI under 35.

• Esophageal motility confirmed to be normal on manometry.

• Reflux that persists despite medication.

The decision should follow a complete workup: endoscopy, barium study, pH testing, and high-resolution manometry (Hawasli et al., American Journal of Surgery, 2019; Cammarata et al., Obesity Surgery, 2024).

‍

Usually not. Stretta is generally not a good option for reflux after a sleeve. Reflux is common after sleeve gastrectomy, affecting roughly 20–30% of patients over the long term. Causes include a hiatal hernia, a narrowing or twist of the sleeve, the sleeve moving up into the chest, and the high-pressure tube the sleeve creates working against a weakened lower esophageal sphincter (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026).

Stretta tightens and thickens the sphincter muscle with radiofrequency energy. It does not correct any of these anatomic problems. The only published study of Stretta after a sleeve followed 15 patients for 6 months, with these results:

• Reflux symptom scores did not improve significantly.

• Two-thirds of patients were dissatisfied.

• Only 20% were able to stop acid-reducing medication.

• About 13% went on to need conversion to gastric bypass.

• One patient had bleeding after the procedure (Khidir et al., Obesity Surgery, 2018; Rapolti et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2024).

SAGES recommends Stretta only for patients who have not had bariatric surgery and do not have a hiatal hernia or severe esophagitis (Rapolti et al., Journal of Laparoendoscopic & Advanced Surgical Techniques, 2024).

For post-sleeve reflux that does not respond to medication, the most effective treatment is usually conversion to Roux-en-Y gastric bypass, which resolves reflux symptoms in 60–100% of patients. Magnetic sphincter augmentation (LINX) and hiatal hernia repair are options for selected patients who are not good candidates for bypass (Vosburg et al., American Society for Metabolic and Bariatric Surgery, 2026). The first step is a thorough evaluation with endoscopy, a barium study, pH testing, and manometry to find the cause of the reflux (El Nakeeb et al., Obesity Surgery, 2022).

‍

Yes. Sleeve gastrectomy can worsen existing reflux or cause new reflux in some patients because it creates a higher-pressure stomach tube and can alter the anti-reflux barrier. Some patients develop erosive esophagitis or Barrett's esophagus, sometimes without symptoms. Patients with significant reflux are often better served by gastric bypass, and reflux after a sleeve can be treated with medication or conversion to bypass.

Yes. Gastric bypass is generally the preferred bariatric operation for patients with reflux, because the small pouch makes little acid and bile is diverted away from the esophagus. Sleeve gastrectomy, in contrast, can worsen existing reflux or cause new reflux in some patients. For patients with significant reflux, a hiatal hernia or Barrett's esophagus, bypass is usually recommended, and patients with reflux after a sleeve often do well with conversion to bypass.

It can. Reflux is the main reason a re-sleeve isn't right for everyone. Making the sleeve narrower again raises pressure inside the stomach, and sleeve anatomy is already linked to reflux. In a 2026 U.S. series of 101 re-sleeve patients, use of reflux medication increased significantly after surgery, although symptoms generally stayed controlled (Ma et al., Surgery for Obesity and Related Diseases, 2026). A network meta-analysis found higher rates of worsening or new reflux after re-sleeve than after conversion to gastric bypass or SADI-S (Salman et al., World Journal of Surgery, 2024).

That is why reflux symptoms, esophagitis, or Barrett's esophagus generally rule out re-sleeve. In those cases, conversion to Roux-en-Y gastric bypass is the preferred operation because it treats both the weight regain and the reflux (Antonopulos et al., Obesity Surgery, 2019). See Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion and Gastric Bypass (Roux-en-Y) for GERD.

‍

It can, and that's why reflux testing comes first.

DS keeps your sleeve and pylorus, so it doesn't remove the high-pressure anatomy that causes reflux after sleeve. In pooled data:

• 18% of patients developed new reflux after DS

• 14% with existing reflux got worse

• About half improved

• 4–12% eventually needed reflux surgery (Brand et al., Surgical Endoscopy, 2025)

If you have reflux, esophagitis, Barrett's esophagus, or a hiatal hernia, conversion to Roux-en-Y gastric bypass is generally the better choice (Merz et al., Surgery for Obesity and Related Diseases, 2019). See Sleeve Gastrectomy to Roux-en-Y Gastric Bypass Conversion.

‍